3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
4
Unknown
3
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
1
Leukemia
1
Interventions
Capecitabine
25
Oxaliplatin
24
Paclitaxel
23
Gemcitabine
21
Cisplatin
21
Fluorouracil
20
Carboplatin
18
Drug Therapy
17
Docetaxel
17
pembrolizumab
15
Leucovorin
15
Irinotecan
15
Radiotherapy
12
tislelizumab
11
Injections
10
Radiation
9
Pemetrexed
9
Magnetic Resonance Spectroscopy
9
Bevacizumab
9
toripalimab
8
Cetuximab
8
Surgical Procedures, Operative
7
Specimen Handling
7
Radiotherapy, Intensity-Modulated
7
Azacitidine
7
venetoclax
6
sintilimab
6
atezolizumab
6
Topotecan
6
Cyclophosphamide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Not yet recruiting
×
Arsenic Trioxide
×
Clear all
NCT07296445
2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3
Not yet recruiting
120 enrolled